Juan Domingo Gispert

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andréa Lessa Benedet, Marta Milà‐Alomà, Agathe Vrillon et al. · JAMA Neurology · 2021 · 566 citations · Full text

<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Marc Suárez‐Calvet, Gernot Kleinberger, Miguel Ángel Araque Caballero et al. · EMBO Molecular Medicine · 2016 · 503 citations · Full text

Immunology, Neurochemical Biomarkers, Social Sciences +20

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

Stephan P. Tenbaum, Paloma Ordóñez‐Morán, Isabel Puig et al. · Nature Medicine · 2012 · 395 citations · Full text

Subverts Foxo3a, Oncology, Medicine +10

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s <i>continuum</i> when only subtle changes in Aβ pathology are detected

Marc Suárez‐Calvet, Thomas K. Karikari, Nicholas J. Ashton et al. · EMBO Molecular Medicine · 2020 · 392 citations · Full text

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Marta Milà‐Alomà, Nicholas J. Ashton, Mahnaz Shekari et al. · Nature Medicine · 2022 · 341 citations · Full text